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Purpose: Anaplastic thyroid cancer (ATC) is a rare tumor with a lethal clinical course despite aggressive multimodal therapy. 
Intensity-modulated radiotherapy (IMRT) may achieve a good therapeutic outcome in ATC patients, and the role of IMRT should be 
assessed. We retrospectively reviewed outcomes for ATC treated with three-dimensional conformal radiotherapy (3D-CRT) or IMRT 
to determine the optimal treatment option and explore the role of radiotherapy (RT). 
Materials and Methods: Between December 2000 and December 2015, 41 patients with pathologically proven ATC received 
RT with a sufficient dose of ≥40 Gy. Among them, 21 patients (51%) underwent surgery before RT. Twenty-eight patients received 
IMRT, and 13 received 3D-CRT. Overall survival (OS) and progression-free survival (PFS), patterns of failure, and toxicity were 
examined.
Results: The median follow-up time for survivors was 38.0 months. The median and 1-year OS and PFS rates were 7.2 months and 
29%, 4.5 months and 15%, respectively. Surgery significantly improved the prognosis (median OS: 10.7 vs. 3.9 months, p = 0.001; 
median PFS: 5.9 vs. 2.5 months, p = 0.007). IMRT showed significantly better PFS and OS than 3D-CRT, even in multivariate analysis 
(OS: hazard ratio [HR] = 0.30, p = 0.005; PFS: HR = 0.33, p = 0.005). Significantly higher radiation dose could be delivered with IMRT 
than 3D-CRT (EQD210 66 vs. 60 Gy, p = 0.005). Only 2 patients had grade III dermatitis after IMRT. No other severe toxicity ≥grade III 
occurred. 
Conclusion: Patients with ATC showed better prognosis through multimodal treatment. Furthermore, IMRT could achieve 
favorable survival rates by safely delivering higher dose than 3D-CRT.
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Introduction
Anaplastic thyroid carcinoma (ATC) is a rare tumor, that 
accounts for <5% of all thyroid cancers. However, it is one of 
the most aggressive human cancers, causing up to 40% of all 
thyroid cancer deaths [1,2]. Survival is limited to 3–6 months 
due to very aggressive tumor biology. ATC can invade adjacent 
organs, such as the larynx, trachea, esophagus, vessels, and 
muscles, resulting in dyspnea, vocal cord paralysis,  dysphagia, 
and consequently, mortality. Not only uncontrolled local 
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tumor invasion but also distant metastases (DM) can cause 
cancer deaths [3-7]. Because of its dismal features, all ATC 
are classified as stage IV according to the American Joint 
Committee on Cancer Staging (AJCC) staging system (7th 
edition), regardless of tumor size, nodal status, and either 
absence or presence of DM [7-11]. 
Treatment options for ATC are generally recommended 
a s  m u l t i m o d a l  t h e r a p i e s  i n c l u d i n g  s u r g e r y  a n d 
chemoradiotherapy, which might offer opportunities to 
prolong survival or improve the quality of life. However, even 
with the very best treatment, an extremely low cure rate has 
been reported in ATC in many recent studies [12,13]. Thus, 
the optimal multimodal therapy policy is still debated, and a 
standardized treatment strategy remains unestablished [12-
14].
Considering these unsatisfactory results, there is a need to 
introduce more advanced treatment technique to enhance 
therapeutic outcomes in ATC. For radiotherapy (RT) modality, 
the efficacy of conventional three-dimensional conformal 
radiotherapy (3D-CRT) is potentially limited by undesirable dose 
reductions due to toxicity related to the anatomical location of 
the thyroid gland. Intensity-modulated radiotherapy (IMRT), an 
advanced form of RT, can successfully deliver high doses to the 
tumor while surrounding normal tissues receive only low doses 
of radiation. IMRT might achieve a good therapeutic outcome, 
and contribute to longer survival when IMRT is combined with 
the aggressive multimodal therapy [15].
In this study, we investigated institutional therapeutic 
outcomes of patients with ATC who received RT at our 
institution and assessed survival outcomes to determine 
the optimal treatment modality. Furthermore, we attempted 
to demonstrate the difference in clinical outcomes after 
performing a modern RT technique.
Materials and Methods
1. Patients
We identified 59 patients with pathologically proven ATC who 
received RT between December 2000 and December 2015 in 
Yonsei University Health System. A total of 18 patients who 
received an insufficient radiation dose <40 Gy due to rapid 
tumor progression, who refused treatment were excluded; 
therefore, the outcomes of 41 patients were analyzed in 
this study. The medical records of these patients were 
retrospectively reviewed. Initial evaluation included physical 
examination, routine labs, computed tomography (CT) scans 
of the neck and chest, and positron emission tomography. The 
AJCC staging system (7th edition) was used for tumor staging. 
The final pathologic confirmation was done by surgery in 21 
patients, open biopsy in 4 patients, and fine-needle aspiration 
biopsy in 16 patients. The histologic findings were examined 
by a pathologist to exclude possible poorly differentiated 
carcinoma. This study was approved by the Institutional Review 
Board of the Yonsei University Health System (No. 3-2018-
0093). The patient records/information were anonymized and 
de-identified prior to analysis, and informed consent was not 
obtained from each participant. 
2. Treatment
Surgical therapy for ATC included radical resection for patients 
with resectable tumors and partial/palliative resection for 
the remaining patients with unresectable tumors. Radical 
resection was usually done as total thyroidectomy because 
ATC usually shows aggressive behavior and extensive tumor 
burden at presentation. Partial thyroidectomy was performed 
when there was little tumor burden, and when the tumor 
is focally limited in the unilateral lobe. For patients with 
clinically positive cervical lymph nodes, level II to VI neck node 
dissection was also performed. When patients were unable 
to undergo surgery due to poor general condition, old age, 
extensive tumor burden (including DM), or refusal of surgery, 
they underwent tracheostomy and tumor biopsy alone. 
For chemotherapeutic regimens, doxorubicin, cisplatin, and 
paclitaxel-based concurrent chemoradiotherapy (CCRT) was 
usually administered before and after surgery in our institution 
according to the clinicians’ preferences and patients’ condition. 
If patients could not tolerate CCRT, physicians sometimes 
decided to perform RT only. Sequential chemotherapy with 
doxorubicin, cisplatin, and paclitaxel after CCRT was also 
considered if it was necessary. 
For RT, all patients were in the supine position using a 
thermoplastic mask, and a contrast-enhanced 3 mm-thickness 
slice cut CT scan was obtained. The CT scan was imported to 
the Pinnacle3 planning system version 9.4 (Philips Medical 
Systems, Cleveland, OH, USA) and MIM software version 
6.5.8 (MIM Software Inc., Cleveland, OH, USA), and the target 
volume was delineated on each of the axial CT images by an 
experienced radiation oncologist. In the 2000s, patients were 
mainly treated with the 3D-CRT technique, but as IMRT began 
to be covered by Korean national health insurance, IMRT 
gradually became the predominant modality.
For the RT field, gross tumor volume (GTV) was defined as 
the primary tumor and metastatic lymph nodes in patients 
without surgery whereas in patients with surgery, it was 
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defined as postoperative tumor bed. The clinical target volume 
(CTV) included the thyroid area and regional lymph node areas 
for elective treatment (e.g., bilateral neck level II–VI, upper 
mediastinum). The planning target volume (PTV) was defined 
as CTV plus a 0.3-cm margin. For 3D-CRT, the median total 
radiation dose to the GTV for definitive treatment was 60.0 
Gy (range, 51.3 to 67.0 Gy), delivered in single daily fractions 
of median 2.0 Gy (range, 1.8 to 2.5 Gy), 5 days a week, for a 
median total of 30 fractions (range, 24 to 36 fractions). For 
postoperative cases, median dose to the tumor bed was 55.8 
Gy (range, 53.1 to 63.7 Gy), delivered in single daily fractions 
of 1.8 Gy for a median total of 32 fractions (range, 30 to 36 
fractions). The dose administered to regional lymph nodes 
areas was median 40.7 Gy (range, 30 to 67.0 Gy), with a 
median fractional dose of 1.8 Gy (range, 1.8 to 2.5 Gy), for 
a median 22 fractions (range, 15 to 30 fractions). For IMRT, 
the median radiation dose to the GTV for definitive treatment 
was 67.1 Gy (range, 43.5 to 74.8 Gy), delivered in single daily 
fractions of median 2.5 Gy (range, 2.0 to 3.0 Gy), 5 days a 
week, for a median total of 26 fractions (range, 20 to 33 
fractions). For postoperative cases, median dose to the tumor 
bed was 64.2 Gy (range, 57.3 to 67.7 Gy) delivered in single 
daily fractions of median 2.2 Gy (range, 2.0 to 2.7 Gy), for a 
median total of 30 fractions (range, 22 to 32 fractions). The 
dose administered to regional lymph nodes areas was median 
48.9 Gy (range, 35.4 to 60.4 Gy) with a median fractional 
dose of 1.8 Gy (range,1.6 to 2.2 Gy), for a median 30 fractions 
(range, 20 to 33 fractions). The simultaneous integrated boost-
IMRT (SIB-IMRT) technique was used for IMRT. Therefore, some 
patients with IMRT received a higher dose in the GTV area 
using the SIB technique than did patients with 3D-CRT, while 
simultaneously delivering a lower dose to the normal tissues.
3. Treatment outcome and toxicity
Clinicians routinely examined patients at least once a week 
during the RT, and 1 month following the completion of RT 
for toxicity assessment, which included a complete blood 
count (CBC) test. If clinically indicated, other blood tests or 
imaging studies such as CT scans were obtained. Toxicity was 
graded according to the Common Terminology Criteria for 
Adverse Events (CTCAE v.4.0). Acute toxicity was defined as an 
event occurring during RT or within 90 days from the start of 
RT. Late toxicity was defined as an event occurring after 90 
days from the start of RT. Acute or late toxicity ≥grade 3 was 
considered severe.
For follow-up, patients were evaluated at 3-month intervals 
for the first 2 years, and every 6 months thereafter. The 
first treatment response was evaluated using the Response 
Evaluation Criteria in Solid Tumors Group (RECIST) at the first 
visit after completing RT. Routine follow-up included neck 
and chest CT scans and CBC. All patients were followed until 
death or time of analysis. When recurrence or metastasis was 
suspected, imaging studies including CT scan were performed 
for further assessment. Locoregional failure (LRF) was defined 
as any recurrence inside the neck area (thyroid tumor bed as 
‘local failure’ and lymph nodes as ‘regional failure’) with or 
without DM. All other recurrences outside the neck area were 
defined as DM.
4. Statistical analysis
Progression-free survival (PFS) was defined as the time from 
the date of first treatment to any recurrence or last follow-
up. Overall survival (OS) was defined as the time from the 
date of first treatment to the time of death from any cause 
or last follow-up. Survival rates were calculated using the 
Kaplan-Meier method, and prognostic impacts of clinical 
factors were analyzed with the log-rank test. Cox regression 
was used for analysis of independent prognostic factors. After 
univariate analysis of survival, we chose significant factors 
and generated multivariate cox regression model. Comparisons 
of basic characteristics between groups were done using the 
chi-square test. Student t-test analysis was also performed 
to assess the differences between the continuous variables of 
two different groups. SPSS version 23 (IBM, Armonk, NY, USA) 
was used for statistical analyses. The p-values less than 0.05 
were considered statistically significant. 
Results
1. Clinical and pathological characteristics
The patient and tumor characteristics are summarized in Table 
1. There were 41 patients, including 24 females and 17 males 
with a ratio of 1.4:1.0. The age ranged from 43 to 86 years 
old, with a median of 67.2 years. Five patients had stage IVA 
disease (tumor limited to the thyroid), 20 patients had IVB 
disease (thyroid capsule penetrated), and 16 patients had IVC 
disease (exhibiting distant metastasis). For nodal status, 7 
patients had N0 disease, 6 patients had N1a disease, and 28 
patients had N1b disease. Among 16 patients with stage IVC, 
the most common distant metastases sites were lung only 
(n = 10), followed by bone only (n = 4), and multiple sites 
simultaneously (n = 2). 
Twenty-one out of 41 patients underwent surgery initially. 
Total thyroidectomy was performed in 18 patients, and 
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partial thyroidectomy in 3 patients. Four patients underwent 
tracheostomy alone, without thyroidectomy. Subsequently, 31 
out of 41 patients received chemotherapy. Among them, 12 
patients received doxorubicin-based CCRT, 9 patients received 
cisplatin-based CCRT, 6 patients received paclitaxel-based 
CCRT, and 1 patient received doxorubicin-cisplatin combination 
CCRT. Three received sequential chemotherapy after RT (1 with 
doxorubicin, 1 with cisplatin, and 1 with paclitaxel). 
All patients received RT (n = 41). For modality, 28 patients 
received IMRT and 13 received 3D-CRT. The median total 
EQD210 dose was 63.7 Gy, and the dose varied from 43.5 to 
74.8 Gy. The median dose per fraction was 2.2 Gy (range, 1.8 
to 3.0 Gy), and the median number of fractionations was 30 
(range, 20 to 36 fractions). The median dose for IMRT was 
significantly (p = 0.005) higher than that of 3D-CRT (66.0 Gy 
and 60.0 Gy, respectively).
1. Survival and prognostic factors 
The median follow-up time was 38.0 months (range, 5.1 to 
60.2 months) for surviving patients and 7.2 months (range, 1.2 
to 60.2 months) for the entire cohort. Six out of 41 patients 
were alive at the last follow-up date. Among 35 deaths, the 
most common cause of death was an aggravation of lung 
metastases in 19 patients. Only 2 patients died of local tumor 
progression, and 1 of them underwent salvage surgery for this. 
The other causes of death included brain metastasis, infection 
including sepsis, and poor general condition. 
The median OS was 7.2 months, and the 1-year OS was 29% 
(Fig. 1). In univariate analysis, AJCC stage, and whether the 
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Fig. 1. Kaplan-Meier survival analysis of all 41 patients 
with anaplastic thyroid carcinoma. OS, overall survival; PFS, 
progression-free survival.
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patient had undergone surgery were also significant factors. 
Stage IVA patients had a better OS (median 69.0 months, 
1-year 80%) than stage IVB (median 8.0 months, 1-year 25%) 
or stage IVC patients (median 3.9 months, 1-year 19%) (p 
= 0.007). Patients who underwent surgery had a better OS 
(median 10.7 months, 1-year 43%) than patients without 
surgery (median 3.9 months, 1-year 15%) (p = 0.001) (Fig. 2A). 
In multivariate analysis of OS, stage IVA (HR 0.04, p = 0.004 to 
others), surgery (HR 0.27, p = 0.001), and IMRT (HR 0.30, p = 
0.005) were found to be independently significant factors. 
The median PFS was 4.5 months, and the 1-year PFS was 
15% (Fig. 1). In univariate analysis, AJCC stage, RT modality, 
and whether the patient had undergone surgery were 
significant prognostic factors. Stage IVA patients had a better 
PFS (median 48.0 months, 1-year 60%) than stage IVB (median 
5.1 months, 1-year 10%) or stage IVC patients (median 2.3 
months, 1-year 6%) (p = 0.010). Patients who were treated 
with IMRT had a better PFS (median 5.1 vs. 2.6 months, 1-year 
18% vs. 8%) (p = 0.049). Patients who underwent surgery 
had a better PFS (median 5.9 months, 1-year 19%) than 
those without surgery (median 2.5 months, 1-year 10%) (p 
= 0.007) (Fig. 2B). In multivariate analysis, stage IVA (hazard 
ratio [HR] = 0.14, p = 0.005 to others), surgery (HR = 0.47, p = 
0.026), and IMRT (HR = 0.33, p = 0.005) were still found to be 
significant factors. The survival analyses of potential variables 



















































































Fig. 2. Kaplan-Meier survival analysis on overall survival (A) and progression-free survival (B) in patients with surgery or not. RT, 
radiation therapy.
Table 2. Univariate and multivariate analysis of survival rates
Variable
OS PFS
Univariate Multivariate Univariate Multivariate











































































OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology 
Group performance score; IMRT, intensity-modulated radiotherapy. 
*p < 0.05. 
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2. Patterns of failure
During the median follow-up duration of 7.4 months, 
recurrences developed in 32 patients (78%). In 32 patients with 
failures, DM was the most dominant failure pattern (n = 25/32, 
78%) followed by LRF (n = 20/32, 63%). DM was observed 
most commonly in the lungs (n = 22), followed by the non-
regional lymph nodes (n = 4), bone (n = 3), liver (n = 1), brain 
(n = 1), and heart (n = 1). Local failure occurred in 13 patients 
(41%), and regional failure occurred in 7 patients (22%). The 
LRF rate was reduced significantly after surgery with RT than 
after RT only (1 year 80% vs. 44%, p = 0.019). However, the 
DM rate did not differ significantly with treatment modality 
(with surgery vs. without surgery: 28% vs. 24%). There was no 
difference between IMRT and 3D-CRT in the LRF rate (p = 0.280) 
or DM rate (p = 0.960).
3. Subgroup analyses according to treatment modality 
Subgroup analyses were performed for patients with surgery 
(‘Adjuvant RT’, n = 21) or not (‘Primary RT’, n = 20). The patient 
and treatment characteristics between the two groups are 
compared in Table 3. There were significantly more stage IVC 
patients in the primary RT group (65.0% vs. 14.3%, p = 0.002).
In the adjuvant RT group, there was no significant 
prognostic factor for OS and PFS, although there was a 
tendency of better survival when treated with IMRT (IMRT vs. 
3D-CRT: 1-year OS 47% vs. 25%, p = 0.949; 1-year PFS 24% 
vs. 0%, p = 0.323). 
In contrast, there were different results in the primary 
RT group (Table 4). In the univariate analyses of PFS, high-
dose RT with EQD210 dose ≥62 Gy showed a significant better 
survival than EQD210 dose <62 Gy (HR = 0.32, p = 0.031). 
Performing chemotherapy also showed a better survival than 
no chemotherapy (HR = 0.14, p = 0.002). There were similar 
results in the analyses of OS. RT with EQD210 dose ≥62 Gy 
also showed a significantly better OS than EQD210 <62 Gy (HR 
= 0.16, p = 0.003). Furthermore, performing chemotherapy 
showed a significant better 1-year OS than not performing 
chemotherapy (HR = 0.07, p = 0.001). According to RECIST 
criteria, complete response, partial response, and stable disease 
were noted in 41%, 31%, and 28%, respectively. In Fig. 3, 
we present a case of 67-year-old male patient in primary RT 
group with EQD210 dose ≥62 Gy, chemotherapy, and IMRT. This 
Table 3. Patients’ characteristics according to whether they underwent surgery 
Variable Primary RT (n = 20) Adjuvant RT (n = 21) p-value



























































Values are presented as number (%).
RT, radiation therapy; ECOG PS, Eastern Cooperative Oncology Group performance score; IMRT, intensity-modulated radiotherapy; 
3D-CRT, three-dimensional conformal radiotherapy.
Radiotherapy for anaplastic thyroid cancer
109www.e-roj.orghttps://doi.org/10.3857/roj.2018.00045
patient lived for 17.8 months. 
The patient and treatment characteristics of the 3D-CRT (n 
= 13) and IMRT (n=28) group are compared in Table 5. More 
patients received EQD210 dose ≥62 Gy in the IMRT group than 
the 3D-CRT group (IMRT 82.1% vs. 3D-CRT 38.5%, p = 0.005). 
The median EQD210 dose for the 3D-CRT group was 60.0Gy, 
whereas the EQD210 dose for the IMRT group was 66.0 Gy.
4. Toxicity
Acute toxicities included anorexia, nausea, vomiting, fatigue, 
esophagitis, skin reaction, and xerostomia. Thirty-two 
patients (78%) experienced acute toxicities, and esophagitis/
pharyngitis was the most common side effect (27/41, 66%). 
All esophagitis/pharyngitis were grade I or II toxicities only (n 
= 7 and n = 20, respectively), and none required tube feeding 
Table 4. Univariate analysis of survival in the primary RT group
Variable
OS PFS




Stage (IVA vs. others)
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Chemotherapy 











































RT, radiation therapy; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; IMRT, 
intensity-modulated radiotherapy; OS, overall survival; PFS, progression-free survival. 
*p < 0.05.          
Table 5. Patients’ characteristics according to radiation modality
Variable 3D-CRT (n = 13) IMRT (n = 28) p-value
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3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; ECOG PS, Eastern Cooperative Oncology 
Group performance score; RT, radiation therapy.
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support. Skin reaction developed in 12 patients (29%). Among 
them, grade I occurred in 2 patients, grade II in 8 patients, and 
grade III in 2 patients. One patient with grade III dermatitis 
was admitted and received daily dressing. After 3 weeks of 
rest, this patient was able to restart RT. In the other patient 
with grade III dermatitis, 2 weeks of rest from RT was required, 
Fig. 3. Results after intensity-modulated radiation therapy: a patient in the primary RT group. A male patient received a diagnosis of 
anaplastic thyroid cancer at the age of 67 years. Fine-needle aspiration biopsy revealed an anaplastic carcinoma of right thyroid gland. 
(A) There was a 5.5cm sized lobulated bulky mass at right thyroid gland with direct invasion of trachea at the time of diagnosis. (B) 
Concurrent chemoradiotherapy with paclitaxel was administered. The isodose lines represent 106% of prescribed dose (EQD210 dose of 
70 Gy, yellow), 100% (66 Gy, red), 100% of the prescribed dose at lymph node area (48 Gy, blue). (C) Six months after radiation therapy, 
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and RT could be successfully continued and finished with the 
skin-sparing adaptive plan after 25 fractions. Except for these 
cases of grade III dermatitis, no other acute toxicity ≥grade III 
occurred in all patients. There were no late adverse effects of 
therapy until the last follow-up date. Furthermore, there was 
no difference in toxicity according to RT modality.
Discussion and Conclusion
This study reviewed the institutional treatment outcome of 
ATC after RT. A better survival was noted in the patients who 
received aggressive multimodal therapy including surgical 
resection and chemotherapy. The IMRT group showed a better 
prognosis than the 3D-CRT group by safely delivering a higher 
radiation dose. 
ATC is a malignant thyroid tumor that has a dismal clinical 
course and very low survival rate compared to other thyroid 
malignancies. To date, there have been no published phase 
III trials of ATC yet. The rarity of this disease entity combined 
with its aggressive nature makes randomized clinical trials 
difficult. Most of the available evidence is from retrospective 
studies, which suggest that the combination of surgery, RT, 
and chemotherapy may yield favorable results. According 
to the recent National Comprehensive Cancer Network 
(NCCN) Guidelines, the recommended treatment of ATC is 
surgical resection and adjuvant therapy including RT and 
chemotherapy [16]. 
Single-modality therapy has been shown to have limited 
effect on locoregional disease recurrence and survival [17]. 
Therefore, multimodal therapy has progressively become 
the treatment of choice for ATC, with surgery being the 
cornerstone of patient management. Moreover, due to the 
threat of early metastatic spread, therapeutic options in ATC 
must combine local and systemic treatments. In a retrospective 
study in Germany [18], 9 patients with ATC underwent 
multimodal treatment consisting of surgery followed by 
postoperative RT with or without chemotherapy. An improved 
survival at 24 months was found in univariate analysis for 
CCRT (p = 0.018) than RT alone and symptoms were controlled 
at the end of RT (p = 0.030). Similarly, in our study, adjuvant 
RT after surgery was administered to 21 patients, and better 
prognosis was noted among them. Moreover, 3 patients who 
underwent aggressive multimodal therapy despite of the stage 
IVC disease showed favorable OS of 56, 21, and 6 months, 
respectively. 
The total radiation dose is known to be related to the 
LRF of ATC, which leads to dyspnea and tracheostomy. In a 
retrospective study on 75 patients with ATC, Swaak-Kragten 
et al. [19] reported that the median OS of patients who had 
received a total dose of >40 Gy versus ≤40 Gy, was 5.4 and 
1.7 months, respectively (p < 0.001). Another study indicated 
that the median survival of 24 patients who received ≥40 Gy 
was longer than that of 34 patients who received <40 Gy (9 
vs. 3 months) [20]. In a meta-analysis of 3,552 patients in 
the National Cancer Database by Glaser et al. [21], a radiation 
dose greater than 59.4 Gy showed significantly better survival. 
Although it is difficult to directly compare outcomes among 
studies due to the differences in surgery extent and RT aim, a 
higher radiation dose seems to contribute to a better survival 
outcome. Similarly, although our results showed no difference 
in outcome in the entire cohort, significantly higher survival 
rates were seen with EQD210 ≥62 Gy in the primary RT group.
IMRT provides a relatively more conformal high dose to 
the gross tumor and high-risk areas with better homogeneity, 
compared to the 3D-CRT technique. At the same time, 
normal organs at risk receive less radiation using the IMRT 
technique, which achieves superior therapeutic ratio. Lim et 
al. [8] retrospectively reviewed the treatment outcome of 13 
consecutive patients who treated in our institution between 
2006 and 2010. Among them, 5, 2, and 6 patients had stage 
IVA, IVB, and IVC disease, respectively. They received 3D-CRT 
and chemotherapy plus surgery, and an unfavorable outcome 
was reported (median PFS and OS: 2.8 and 3.8 months, 
respectively). Foote et al. [22] reported 10 patients with 
regionally confined disease who were treated with aggressive 
therapy combining surgery, IMRT, and chemotherapy. Five 
patients (50%) were alive and disease-free, and OS at 1 and 2 
years was 70% and 60%, respectively. He et al. [15] examined 
the treatment results of 13 patients treated with IMRT. At a 
median follow-up duration of 12 months, the median survival 
was 9 months. The locoregional disease was in complete 
remission in 2 patients, partial remission in 1 patient, stabilized 
in 7 patients and progressive disease in 3 patients. Distant 
metastases were found in 7 patients. 
When we compare our results with those of Lim et al. 
[8], 3D-CRT with or without aggressive multimodal therapy 
showed similar PFS and OS (3.1 and 3.9 months, respectively) 
with a different patient cohort, whereas IMRT showed better 
PFS and OS (5.9 and 8.0 months, respectively). These outcomes 
are favorable results similar to other previous IMRT-related 
reports. Furthermore, more patients received an EQD210 dose 
≥62 Gy in the IMRT group than in the 3D-CRT group (IMRT 
82.1% vs. 3D-CRT 38.5%, p = 0.005), while significant higher 
survival rates were seen with EQD210 >62 Gy in the primary 
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RT group (HR 0.16, p = 0.003 for OS; HR = 0.32, p = 0.031 for 
PFS) in univariate analysis. This improved prognosis is probably 
from the conformity and dose difference between IMRT and 
3D-CRT (IMRT 66.0 Gy vs. 3D-CRT 60.0 Gy, p = 0.005), even 
though it was not possible to calculate the exact conformity 
index between the two groups in this study.
Chemotherapy is one of the effective treatment strategies 
proposed for ATC. Haigh et al. [23] confirmed that adjuvant 
CCRT after surgery can improve the survival rate. Busnardo et 
al. [24], also suggested that neoadjuvant CCRT improves the 
tumor resection rate and prognosis. However, McIver et al. [25] 
found that comprehensive treatment with surgery and CCRT 
did not significantly prolong survival time. Our study also 
could not reveal that chemotherapy prolonged PFS and OS 
in the entire cohort. The positive effect of chemotherapy was 
suggested only in the subgroup without surgery. Randomized, 
prospective trials with larger sample sizes are required to 
confirm whether modern chemotherapy has a survival benefit 
for ATC.
There are several limitations of this study. First, the sample 
size was small, because of the rarity of ATC and low referral 
rates for RT before the role of aggressive multimodal therapy 
including RT was established. However, compared to other 
retrospective studies on ATC, our sample size was relatively 
large. The second limitation is the relatively short follow-up 
duration of a median 7.4 months for the entire cohort, and 
46.0 months for living patients. However, compared to other 
previous studies, this follow-up duration is not short for 
discussing the outcome of ATC, because ATC is a disease with 
a very aggressive course. Third, since our cohort included only 
patients who received RT, there was a possibility of a selection 
bias. Patients who only underwent surgery without RT were 
not included; therefore, patients who did not need to receive 
RT (e.g., those with small tumors limited to the thyroid) were 
excluded from this study. Furthermore, we included patients 
with advanced-stage tumors, who might not have been able 
to afford surgery. This might result in a shorter survival rate 
compared to previous studies dealing only with postoperative 
RT cases. Further studies based on more diverse cases and 
sufficient follow-up periods would help confirm the results 
of our study. The last limitation is that there might be a 
selection bias. Surgery was a significant factor of OS and PFS 
in univariate and multivariate analysis, but it is not clear if 
surgery directly improves survival. Since resectability depends 
on extent of involved structures, potential morbidity, and 
mortality associated with resection, whether a patient can 
undergo surgery or not might have an influence on survival. 
In conclusion, our study reviewed the institutional 
outcomes of ATC treated with RT, using either IMRT or 3D-CRT. 
We observed increased OS and PFS with surgery or IMRT. 
Aggressive multimodal therapy including surgery, modern 
chemotherapy, and IMRT might further improve the prognosis 
in ATCs, which is known to have a dismal prognosis.
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